Prolonged survival of patients with peripheral T-Cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F09%3A00009474" target="_blank" >RIV/61989592:15110/09:00009474 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/09:00009739

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Prolonged survival of patients with peripheral T-Cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation

Popis výsledku v původním jazyce

Background: Nodal peripheral T-cell lymphomas (PTCLs) are infrequent subtypes of non-Hodgkin?s lymphomas.-The WHO classification recognizes three subgroups of nodal PTCL: peripheral T-cell lymphoma not otherwise specified-(PTCL, NOS), anaplastic large cell lymphoma (ALCL) and angioimmunoblastic lymphoma (AIL). The clinical-course is aggressive and despite multiagent chemotherapy, the median survival is about 2 years. Optimal first-line chemotherapy-is not established and the role of high-dose therapy with autologous stem cell support is still controversial.-Aim: To analyze the long-term outcome of PTCL patients treated with intensive first-line chemotherapy with highdose-therapy and autologous transplant consolidation. Method: Sequential chemotherapy protocol consisting of 3 cycles of CHOEP-21-like regimen (PACEBO), 1 cycle-of an ifosfamide and methotrexate-based regimen (IVAM) and a priming regimen with high-dose cytosine arabinoside-(HAM). Consolidation was provided with myeloablativ

Název v anglickém jazyce

Prolonged survival of patients with peripheral T-Cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation

Popis výsledku anglicky

Background: Nodal peripheral T-cell lymphomas (PTCLs) are infrequent subtypes of non-Hodgkin?s lymphomas.-The WHO classification recognizes three subgroups of nodal PTCL: peripheral T-cell lymphoma not otherwise specified-(PTCL, NOS), anaplastic large cell lymphoma (ALCL) and angioimmunoblastic lymphoma (AIL). The clinical-course is aggressive and despite multiagent chemotherapy, the median survival is about 2 years. Optimal first-line chemotherapy-is not established and the role of high-dose therapy with autologous stem cell support is still controversial.-Aim: To analyze the long-term outcome of PTCL patients treated with intensive first-line chemotherapy with highdose-therapy and autologous transplant consolidation. Method: Sequential chemotherapy protocol consisting of 3 cycles of CHOEP-21-like regimen (PACEBO), 1 cycle-of an ifosfamide and methotrexate-based regimen (IVAM) and a priming regimen with high-dose cytosine arabinoside-(HAM). Consolidation was provided with myeloablativ

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)<br>S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2009

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers

ISSN

1213-8118

e-ISSN

—

Svazek periodika

153

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

4

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—